NCT05164458 2023-12-28Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced MalignanciesInnovent Biologics (Suzhou) Co. Ltd.Phase 1 Unknown320 enrolled
NCT05218148 2022-04-06SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaChineseAMSPhase 2 Unknown44 enrolled